MD Anderson Scientist Awarded Research Grant
Can an epigenetic enzyme under the right conditions contribute to the growth of cancer cells? If so, what happens if the enzyme is removed? Can
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
Can an epigenetic enzyme under the right conditions contribute to the growth of cancer cells? If so, what happens if the enzyme is removed? Can
Having arrived seven weeks ago as the new Chief Development Officer, I have been so inspired by the team spirit of NETRF. From our dedicated
NETRF announces the appointment of Susan Payson as Chief Development Officer. In this new position, Susan will work to expand NETRF’s base of support to
The first step in curing a disease is understanding it. Unfortunately, there is a lot we still don’t know about small-intestinal NETs (SI-NETs). That’s why
by Ronny Allan, NET Patient Activist Doctors and scientists are always looking for better ways to care for patients with cancer; they are looking for
New treatment for GI and pancreatic NETs The U.S. Food and Drug Administration (FDA) has approved Peptide Receptor Radionuclide Therapy (PRRT) with a new radiopharmaceutical for
World renown laboratory in the Netherlands to grown min-organs in Petri dishes to speed up NET drug testing.
Even those who did not know her were inspired by the stories of Meg’s positive, generous spirit, her sense of humor, and ability to squeeze so much life into her 31+years. Nurse Meg took care of us all and is forever in our hearts—forever running alongside encouraging us to dream bigger and live stronger—and find and inspire laughter and joy each day.
There is a critical need to develop improved diagnostic tools for non-invasive, early detection of NETs in a broader range of patients. New grant-funded research will work towards this goal.
He is a pioneer whose work has helped extend the horizon of cancer care, creating a new category of individualized immunotherapy. Carl June, MD, has conducted 25 years of scientific research to advance CAR T-cell therapy. And all that knowledge is now helping to tackle NETs.